Determining Duration of HER2-Targeted Therapy Using Stem Cell Extinction Models

INTRODUCTION: Trastuzumab dramatically improves survival in breast cancer patients whose tumor overexpresses HER2. A subpopulation of cells in human breast tumors has been identified with characteristics of cancer stem cells. These breast cancer stem-like cells (BCSCs) rely on HER2 signaling for sel...

Descripción completa

Detalles Bibliográficos
Autores principales: Riley, Lindsay, Zhou, Hua, Lange, Kenneth, Sinsheimer, Janet S., Sehl, Mary E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532453/
https://www.ncbi.nlm.nih.gov/pubmed/23284608
http://dx.doi.org/10.1371/journal.pone.0046613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532453/
https://www.ncbi.nlm.nih.gov/pubmed/23284608
http://dx.doi.org/10.1371/journal.pone.0046613

Ejemplares similares